Sangamo Therapeutics, Inc.

LSE:0R1D Stock Report

Market Cap: US$253.5m

Sangamo Therapeutics Management

Management criteria checks 3/4

Sangamo Therapeutics' CEO is Sandy Macrae, appointed in Jun 2016, has a tenure of 8.58 years. total yearly compensation is $2.39M, comprised of 29.9% salary and 70.1% bonuses, including company stock and options. directly owns 0.2% of the company’s shares, worth $502.83K. The average tenure of the management team and the board of directors is 3.4 years and 5.2 years respectively.

Key information

Sandy Macrae

Chief executive officer

US$2.4m

Total compensation

CEO salary percentage29.9%
CEO tenure8.6yrs
CEO ownership0.2%
Management average tenure3.4yrs
Board average tenure5.2yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Sandy Macrae's remuneration changed compared to Sangamo Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$135m

Jun 30 2024n/an/a

-US$248m

Mar 31 2024n/an/a

-US$328m

Dec 31 2023US$2mUS$716k

-US$258m

Sep 30 2023n/an/a

-US$250m

Jun 30 2023n/an/a

-US$199m

Mar 31 2023n/an/a

-US$127m

Dec 31 2022US$5mUS$709k

-US$192m

Sep 30 2022n/an/a

-US$178m

Jun 30 2022n/an/a

-US$172m

Mar 31 2022n/an/a

-US$176m

Dec 31 2021US$5mUS$689k

-US$178m

Sep 30 2021n/an/a

-US$181m

Jun 30 2021n/an/a

-US$135m

Mar 31 2021n/an/a

-US$124m

Dec 31 2020US$4mUS$682k

-US$121m

Sep 30 2020n/an/a

-US$76m

Jun 30 2020n/an/a

-US$102m

Mar 31 2020n/an/a

-US$96m

Dec 31 2019US$4mUS$662k

-US$95m

Sep 30 2019n/an/a

-US$118m

Jun 30 2019n/an/a

-US$104m

Mar 31 2019n/an/a

-US$90m

Dec 31 2018US$4mUS$636k

-US$68m

Compensation vs Market: Sandy's total compensation ($USD2.39M) is above average for companies of similar size in the UK market ($USD713.15K).

Compensation vs Earnings: Sandy's compensation has been consistent with company performance over the past year.

CEO

Sandy Macrae (61 yo)

8.6yrs

Tenure

US$2,392,272

Compensation

Dr. Alexander D. Macrae, also known as Sandy, M.B., Ch B, Ph D., MRCP, serves as an Independent Non-Executive Director of 4D pharma plc since August 27, 2019.Dr. Macrae has been the Chief Executive Office...

Leadership Team

NamePositionTenureCompensationOwnership
Alexander Macrae
CEO, President & Director8.6yrsUS$2.39m0.20%
$ 502.8k
Prathyusha Duraibabu
Senior VP5.6yrsUS$1.06m0.040%
$ 100.6k
Nathalie Dubois-Stringfellow
Senior VP & Chief Development Officer6yrsUS$1.03m0.046%
$ 115.8k
Gregory Davis
Head of Research & Technology1.2yrsno data0.019%
$ 49.0k
Aron Feingold
Head of Corporate Communications & Investor Relations Officerno datano datano data
Scott Willoughby
Senior VP3.4yrsno data0.044%
$ 110.4k
Phillip Ramsey
Head of Technical Operations1.7yrsno datano data
Stephanie J. Seiler
Head of Business Development & Alliance Management1.1yrsno datano data
David Ojala
Scientist II - Discovery & Translational Researchno datano datano data
Louise Wilkie
Vice President of Investor Relations & Corporate Communicationsno datano datano data

3.4yrs

Average Tenure

55yo

Average Age

Experienced Management: 0R1D's management team is considered experienced (3.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Alexander Macrae
CEO, President & Director8.6yrsUS$2.39m0.20%
$ 502.8k
H. Parker
Independent Chairwoman of the Board10.6yrsUS$99.28k0.030%
$ 76.1k
Robert Carey
Independent Director8.6yrsUS$80.53k0.024%
$ 60.3k
Stuart Schreiber
Member of Scientific Advisory Board5.2yrsno datano data
Robert Desnick
Member of Scientific Advisory Board5.2yrsno datano data
Roger Kornberg
Member of Scientific Advisory Board5.2yrsno datano data
Samuel A. J. Aparicio
Member of Scientific Advisory Board5.2yrsno datano data
Jef Boeke
Member of Scientific Advisory Board5.2yrsno datano data
Karen Smith
Independent Director6.6yrsUS$76.78k0.025%
$ 63.3k
Megan Levings
Member of Scientific Advisory Board5.2yrsno datano data
Michael Grunstein
Member of Scientific Advisory Board5.2yrsno datano data
Douglas Higgs
Member of Scientific Advisory Board5.2yrsno datano data

5.2yrs

Average Tenure

66.5yo

Average Age

Experienced Board: 0R1D's board of directors are considered experienced (5.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 01:55
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Sangamo Therapeutics, Inc. is covered by 24 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Huidong WangBarclays
Gregory HarrisonBofA Global Research
Jonathan AschoffBrean Capital